Work

Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.603

Authors: Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano, Alvaro Moreno-Aspitia, Sarah A. McLaughlin, John William Winslow, Christos J. Petropoulos, Ahmed Chenna, Michael Patrick Bates, Jodi Marie Weidler, Yolanda Lie, Weidong Huang, Edith A. Perez

Institutions: Mayo Clinic in Florida, Surrozen, Inc. (United States), Mayo Clinic, Assistance Publique – Hôpitaux de Paris, Hôpital Tenon, Pitié-Salpêtrière Hospital, Cepheid (United States), LabCorp (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2670642408

Cites:

Cited by:

Related to: 10